Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Organisation › Details

XenoGesis Ltd.

XenoGesis Ltd. specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and modelling and simulation for human PK and dose prediction. The core XenoGesis team has a proven track record of delivery in drug discovery. Through a consultative approach, the XenoGesis team helps to identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns, providing significant time and cost savings for R&D companies. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis. The organisation combines its state-of-the-art in vitro, in vivo and bioanalytical capabilities with its expert pharmacokinetic/ pharmacodynamic (PK/PD) data interpretation services with GastroPlus™. Their laboratory tests build a full picture of the ADME properties of a molecule including required human drug exposure, backed-up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like’. This unique offering is what makes the XenoGesis service attractive to global drug companies. XenoGesis is a laboratory-based contract research organisation (CRO) based at BioCity in Nottingham and its Founder and CEO is Dr Richard Weaver FRSC. In 2020, XenoGesis was awarded the prestigious Queen’s Award for Enterprise in recognition of its export growth *


Period Start 2011-09-01 established (approx)
  Group Sygnature Discovery (Group)
Products Industry ADME services
  Industry 2 drug development services
Person Person Weaver, Richard (XenoGesis 201109– Managing Director + Founder before AstraZeneca R&D)
Region Region Nottingham, Nottinghamshire
  Country United Kingdom (GB)
  Street Pennyfoot Street
BioCity Nottingham
  City NG1 1GF Nottingham
  Tel +44-115-837-0626
    Address record changed: 2014-01-21
Basic data Employees n. a.
    * Document for �About Section�: Sygnature Discovery Ltd.. (9/24/20). "Press Release: Sygnature Discovery Expands DMPK Capabilities with Acquisition of XenoGesis". Nottingham.
Record changed: 2020-10-01


Picture [iito] Plain Stupid Simple 650x80px

More documents for Sygnature Discovery (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top